Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proteomics and the haematologist.

K S Rees-Unwin1, G J Morgan, F E Davies

  • 1Academic Unit of Haematology and Oncology, University of Leeds, Leeds, UK.

Clinical and Laboratory Haematology
|April 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

Blood cancer journal·2024
Same author

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.

Leukemia·2021
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Leukemia·2017
Same author

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

Blood cancer journal·2017
Same journal

Cystic fibrosis presenting with haematological abnormalities.

Clinical and laboratory haematology·2006
Same journal

T-cell-rich B-cell lymphoma of the spleen presenting with severe hypersplenism.

Clinical and laboratory haematology·2006
Same journal

Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support.

Clinical and laboratory haematology·2006
Same journal

Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia.

Clinical and laboratory haematology·2006
Same journal

Characterization of several amino acid transports and glutamine metabolism in MOLT4 human T4 leukemia cells.

Clinical and laboratory haematology·2006
Same journal

Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma.

Clinical and laboratory haematology·2006
See all related articles

Proteomics offers new ways to understand blood cancers by analyzing proteins. This can lead to better targeted treatments, drug resistance discovery, and faster diagnostics for hematology patients.

Area of Science:

  • Hematology
  • Molecular Biology
  • Biochemistry

Background:

  • Understanding hematological malignancies requires protein-level knowledge for targeted treatments.
  • Molecular pathogenesis, genetic variation, and drug action are key to developing effective therapies.

Purpose of the Study:

  • To review the current use of proteomics technologies in hematology.
  • To explore the future potential of proteomics in identifying diagnostic markers and understanding malignant phenotypes.

Main Methods:

  • Proteomics encompasses technologies like Western blotting, 2D gel electrophoresis, and mass spectrometry.
  • Analysis of the entire proteome in normal and diseased states.

Main Results:

  • Current studies, though limited, show proteomics potential in discovering novel markers.

Related Experiment Videos

  • Identification of proteins linked to drug resistance and tumor biomarkers is feasible.
  • Proteomics can aid in developing rapid clinical diagnostic tests.

    • Conclusions:

    • Proteomics offers significant opportunities for advancing hematology research and clinical practice.
    • Large-scale proteome analysis can identify crucial diagnostic/prognostic markers.
    • Future applications may revolutionize the understanding and treatment of blood cancers.